Business Wire

  1. AGC Biologics Partners With Novelty Nobility For Cell Line Development And Phase I Preparations Of Antibody Drug Candidate 5/5/2025

    AGC Biologics, your friendly CDMO expert, today announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea.

  2. Lantern Advances Drug Candidate LP-184 With IND Clearance For Phase 1b/2 Clinical Trial In Triple Negative Breast Cancer (TNBC) 5/5/2025

    Lantern Pharma Inc., an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial for LP-184 in Triple Negative Breast Cancer.

  3. Iambic Announces Enchant v2, Its Next Generation AI Model For Predicting The Clinical Viability Of Drug Discovery Programs 5/5/2025

    Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, published on major advances to Enchant, Iambic’s breakthrough multimodal transformer model for predicting clinical and preclinical endpoints related to the drug discovery and development process.

  4. Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms And Retains Talent And Infrastructure From Repare Therapeutics To Accelerate Development Of Multi-Modal Antibody Drug Conjugates 5/1/2025

    DCx Biotherapeutics Corporation (“DCx”) today announced an agreement with Repare Therapeutics Inc. (“Repare”) to (i) in-license Repare’s discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the “Transaction”).

  5. Sapient Launches DynamiQ As Its Next-Generation Data Insights Engine For Drug Discovery And Development 4/30/2025

    Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics and real-world data (RWD) human biology database, now branded as the DynamiQ Insights Engine, which increases the speed, versatility, and depth of analyses that Sapient can perform to inform drug discovery and precision drug development strategies.

  6. Thermo Fisher Scientific Leverages Integrated Solutions To Accelerate The Development Of Biologic Therapeutics 4/28/2025

    Thermo Fisher Scientific, the world leader in serving science, is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development.

  7. Innorna Announces FDA Rare Pediatric Disease And Orphan Drug Designations Granted To IN013 For Treatment Of Wilson Disease 4/27/2025

    Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD).

  8. CN Bio And Pharmaron Establish Long-Term Strategic Partnership To Develop OOC Technologies On A Global R&D Platform 4/23/2025

    CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry.

  9. Charles River Leverages Advanced Technology To Expedite Oncology Drug Discovery And Development 4/22/2025

    Charles River Laboratories International, Inc., ahead of the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL, has announced updates to its comprehensive portfolio of products and services supporting the discovery and development of novel oncology drugs.

  10. TNF Pharmaceuticals And Renova Health Utilize AI To Accelerate Drug Development 4/22/2025

    TNF Pharmaceuticals, Inc. (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management.